沛嘉医疗-B(09996.HK)发布公告，于近日，公司收到中华人民共和国国家药品监督管理局的受理通知 书，确认受理TaurusNXT "非醛交联"干瓣经导管主动脉瓣置换("TAVR")系统的注册申请。 | 指标 | 沛嘉医疗-B | 医疗器械II 行业平均 | 行业排名 | | --- | --- | --- | --- | | ROE | -10.75% | -4.03% | 24 29 | | 港股流通市值 | 36.93亿 | 51.77亿 | 11 29 | | 营业收入 | 6.68亿 | 11.95亿 | 15 29 | | 净利率 | -20.14% | -16.5% | 25 29 | | 毛利率 | 70.07% | 54.89% | 62 16 | | 员债率 | 23.63% | 29.03% | 15 29 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 投行对该股的评级以买入为主，近90天内共有1家投行给出买入评级。中信建投最新一份研报给予沛嘉 医疗-B买入评级。 机构评级详情见下表： | 股票代码 股 ...

Macro Strategy - The LPR remained unchanged in November, with the 1-year and 5-year rates at 3.00% and 3.50% respectively, indicating stable monetary policy despite weak macro data in October [2][3] - A-share indices experienced significant declines from November 17 to 21, with the Shanghai Composite Index down 3.90% and the ChiNext Index down 6.15%, primarily due to reduced expectations for a December rate cut by the Federal Reserve [3][4] - All primary industries in the A-share market declined, with energy metals and communication equipment showing the highest cumulative gains for 2025 at 83.18% and 78.97% respectively [5][6] Investment Recommendations - For the long term, 2026 is expected to be a year of growth driven by the "14th Five-Year Plan," with a stable A-share market anticipated [7] - Short-term strategies should focus on sectors benefiting from long-term capital inflows, traditional sectors related to "anti-involution," and consumer areas such as motorcycles and medical services [7] North Exchange Overview - As of November 21, 2025, the North Exchange had 284 listed stocks, with an average total market value of 864.16 billion yuan, a decrease of 4.16% from the previous week [10][11] - Notable new listings included Dapeng Industrial, which saw a 1211.11% increase in its stock price during its first week [10][12] Medical Services Industry - The pharmaceutical and biological sector fell by 6.88%, underperforming the Shanghai Composite Index by 3.11 percentage points [16][17] - The medical services sector's PE ratio is currently at 31.22, with a recent decline of 2.25 [18] - High-growth areas such as ADC and TIDES CDMO are recommended for investment, with companies like WuXi AppTec and WuXi Biologics highlighted [19][20][21] Automotive Industry - Yuanrong Qixing showcased 200,000 mass-produced vehicles at the Guangzhou Auto Show, aiming for a cumulative delivery of 1 million vehicles by 2026 [23][24] - The automotive sector is expected to benefit from the acceleration of intelligent technology adoption and supportive policies for vehicle consumption [25][26] - Investment opportunities are significant in the automotive and parts sectors, particularly for companies involved in smart components and electric vehicles [26][27]